Yordan I.
- Country
- Bulgaria
- Department
- Department of Medical Oncology
Research Overview
- Phase 3 Study of PF-07220060 and Fulvestrant Versus Investigator's Choice in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Post-CDK 4/6 Inhibitor Therapy
- Phase 3 Randomized Double-Blind Study of PF-06821497 and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Comparative Phase 3 Study of GSK5764227, a B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 35 of 235 partner sites.
Specializations
Oncology Focus
This investigator specializes in treating advanced stages of hormone-dependent cancers, with particular emphasis on both breast and prostate malignancies.
- Metastatic castration-resistant prostate cancer management
- HR-positive, HER2-negative breast cancer treatment
- Advanced metastatic disease interventions
The investigator's work encompasses novel therapeutic approaches for patients with progressive disease states.
Therapeutic Innovation
The investigator explores combination therapy approaches in oncology, particularly focusing on hormone-receptor targeted treatments.
- Novel hormonal therapy applications
- Targeted therapeutic combinations
- Progressive disease management strategies
Their work involves evaluating innovative treatment options for patients who have experienced disease progression after initial therapies.
Treatment Optimization
The investigator focuses on developing improved therapeutic strategies for hormone-dependent cancers that have advanced or metastasized.
- Advanced disease intervention protocols
- Endocrine therapy resistance management
- Progressive disease treatment approaches
Their expertise extends to evaluating treatment efficacy in patients with complex disease presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.